Global Congestive Heart Failure
Heart failure (HF) is a rapidly increasing disease worldwide but there is no global HF study that documents demographics, socioeconomic and clinical factors, diagnostic and management patterns, etiology, biomarkers, co-morbidities, treatments, quality of life, barriers to care and outcomes in all parts of the world. Such knowledge is essential in the prevention and treatment of this global disease.
This will be a prospective global registry study of approximately 20,000-25,000 HF patients enrolled over 5 years from North America, South America, Europe, Africa, Asia and the Middle East. Baseline data will be obtained on demographic and socioeconomic data, clinical and laboratory variables, echocardiography, HF etiology, medication use, management patterns, quality of life, barriers to care and health systems. Six-month, 12-month, 18-month and 24-month follow-up data will be obtained to determine changes in management, and patient outcomes. A sub-study of approximately 4000-5000 patients to measure frailty, cognitive and lung function, mental health, medication adherence, patient-reported barriers to care, dietary assessment, and collection of blood samples for central analysis will additionally be performed.
The primary event outcome of the study will be mortality, by cause. Secondary event outcomes will include non-fatal major events (both resulting in and not resulting in hospitalization).
Salim Yusuf, Hisham Dokainish